Therapy for the mucopolysaccharidoses

Valayannopoulos, Vassili; Wijburg, Frits A.
December 2011
Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv49
Academic Journal
Better understanding of disease pathophysiology, improved supportive care and availability of disease-specific treatments for some of the mucopolysaccharidosis (MPS) disorders have greatly improved the outlook for patients with MPS disorders. Optimal management of these multisystemic disorders involves a multidisciplinary team and regular, comprehensive follow-up. Enzyme replacement therapy (ERT) is now available for MPS I (Hurler, Hurler–Scheie and Scheie syndromes) (laronidase), MPS II (Hunter syndrome) (idursulfase) and MPS VI Maroteaux–Lamy (galsulfase), and is in development for MPS IV (Morquio syndrome) and MPS VII (Sly syndrome). Benefits of ERT can include improved walking ability, improved respiration and enhanced quality of life. Haematopoietic stem cell transplantation (HSCT) can preserve cognition and prolong survival in very young children with the most severe form of MPS I, and is under investigation for several other MPS disorders. Better tissue matching techniques, improved graft-vs-host prophylaxis and more targeted conditioning regimens have improved morbidity and mortality associated with HSCT.


Related Articles

  • Overview of the mucopolysaccharidoses. Muenzer, Joseph // Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv4 

    The mucopolysaccharidoses (MPSs) are a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy. The MPSs are heterogeneous, progressive disorders. Patients typically appear normal at birth, but...

  • Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.  // Orphanet Journal of Rare Diseases;2011, Vol. 6 Issue 1, p55 

    The article presents a European consensus procedure which showed the use of enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) in the treatment of patient having mucopolysaccharidosis type I (MPS I). In this procedure a panel of specialists developed...

  • Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.  // Current Medical Literature: Lysosomal Storage Disease;2012, Vol. 10 Issue 1, p28 

    The article focuses on the study regarding the use of hematopoietic stem cell transplantation and enzyme replacement therapy (ERT) for the diagnosis of mucopolysaccharidosis type (MPS I) I patients. It states that MPS IH can in early death, usually within the first 20 years of life, if left...

  • Laronidase.  // BioDrugs;2002, Vol. 16 Issue 4, p316 

    Adis Comments BioMarin Pharmaceutical is developing laronidase, recombinant α-L-iduronidase enzyme replacement therapy for the treatment of mucopolysaccharidosis I (MPS-I) [the most severe form of this is called Hurler syndrome]. The company has received US and European orphan drug...

  • Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies. de Ruijter, J.; Valstar, M. J.; Wijburg, F. A. // Current Pharmaceutical Biotechnology;Jun2011, Vol. 12 Issue 6, p923 

    No abstract available.

  • Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT 2005. Sauer, M.; Meissner, B.; Fuchs, D.; Gruhn, B.; Kabisch, H.; Erttmann, R.; Suttorp, M.; Beilken, A.; Luecke, T.; Welte, K.; Grigull, L.; Sykora, K. W. // Bone Marrow Transplantation;Mar2009, Vol. 43 Issue 5, p375 

    Hurler's syndrome is an inborn error of mucopolysaccharide metabolism leading to premature death in childhood. Allogeneic hematopoietic SCT can achieve long-term survival by correcting the enzymatic deficiency. In an attempt to improve long-term engraftment and to reduce regimen-related toxicity...

  • Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome.  // Current Medical Literature: Lysosomal Storage Disease;2008, Vol. 8 Issue 2, p68 

    The article reports on the result of the study which assesses the effectiveness of enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) in treating patients with mucopolysaccharidosis type I (MPS I) or Hurler syndrome. The study was participated by seven patients...

  • Adult Stem Cells Reverse Multiple Sclerosis. TOWNSEND, LIZ // National Right to Life News;Mar2009, Vol. 36 Issue 3, p6 

    The article presents the results of a Northwestern University trial which showed that 80 percent of multiple sclerosis (MS) patients showed significant improvement of their symptoms after receiving adult stem cells. Physician Richard Burt told the "Chicago Sun-Times" that the trial presented the...

  • Stem-cell therapy for type 1 diabetes. Leavy, Olive // Nature Reviews Immunology;May2007, Vol. 7 Issue 5, p326 

    The article focuses on stem cell transfusion as a potential therapy for type 1 diabetics. Results from a clinical trial reveal that 11 out of the 15 patients subjected to stem cell transplantation became insulin dependent. These imply that people's immune system can be restrained and reset for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics